Lv1
50 积分 2021-04-19 加入
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
1个月前
已关闭
Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY
2个月前
已完结
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
2个月前
已完结
Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial
2个月前
已完结
Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities
1年前
已完结
High-dose chemotherapy for relapsed testicular germ cell tumours
1年前
已完结
Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma
1年前
已完结
Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies
2年前
已完结
CAR T cells and autologous transplantation can coexist for DLBCL
2年前
已完结
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
2年前
已完结
皖公网安备34019202002308
